



Supplementary Figure S7: 5mC levels in primary AML and primary glioma samples and in MCTS lines. (A-C) Total and median 5mC content in primary *IDH-wild-type* (IDH1/2^{WT}) (n=6), *IDH1-mutant* (IDH1^{MUT}) (n=11) and *IDH2-mutant* (IDH2^{MUT}) (n=5) glioma patient samples (A); in primary *IDH wild-type* (IDH1/2^{WT}) (n=5), *IDH-mutant* (IDH1/2^{MUT}) (n=8) and *TET2-mutant* (TET2^{MUT}) (n=5) AML patient samples (B); and in *IDH1 wild-type* (IDH1^{WT}) and *IDH1 R132H-mutant* (IDH1^{R132H}) patient-derived glioma multicellular tumor spheroid (MCTS) lines (C), as measured by LC-MS.